http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109928897-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C311-03 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C311-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C311-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C279-26 |
| filingDate | 2019-04-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-09-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-09-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-109928897-B |
| titleOfInvention | Biguanide derivatives for preventing and treating infarct diseases and application thereof |
| abstract | The invention provides a biguanide derivative for preventing and treating infarct disease and application of the biguanide derivative in preparing medicaments for preventing and treating the infarct disease. The biguanide derivative provided by the invention has antiplatelet effect, has obvious inhibition effect on the formation of pulmonary embolism, arterial thrombosis and venous thrombosis, can effectively reduce cerebral infarction area and cardiac infarction area, has obvious improvement effect on cerebral infarction and cardiac infarction, and has obvious effect superior to that of positive control drug aspirin. The biguanide derivative provided by the invention can also reduce gastrointestinal side effects and bleeding risks commonly existing in the existing clinical antithrombotic drugs. |
| priorityDate | 2019-04-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 106.